Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to -$2.0 million.

  • Lifecore Biomedical, Inc. \De\'s Net Income towards Common Stockholders rose 7109.98% to -$2.0 million in Q2 2025 from the same period last year, while for May 2025 it was -$44.4 million, marking a year-over-year decrease of 28015.27%. This contributed to the annual value of -$44.4 million for FY2025, which is 46925.83% down from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Net Income towards Common Stockholders stood at -$2.0 million for Q2 2025, which was up 7109.98% from -$17.4 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s Net Income towards Common Stockholders' 5-year high stood at $15.6 million during Q1 2024, with a 5-year trough of -$51.6 million in Q2 2022.
  • Its 5-year average for Net Income towards Common Stockholders is -$9.3 million, with a median of -$4.7 million in 2021.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 237678.66% in 2022, then soared by 49439.67% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Net Income towards Common Stockholders (Quarter) stood at -$46.0 million in 2021, then soared by 92.17% to -$3.6 million in 2022, then surged by 494.4% to $14.2 million in 2023, then tumbled by 161.21% to -$8.7 million in 2024, then surged by 76.48% to -$2.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$2.0 million for Q2 2025, versus -$17.4 million for Q1 2025 and -$8.7 million for Q4 2024.